How do I know if I have Malignant hyperthermia?

Malignant hyperthermia is a rare, inherited pharmacogenetic disorder that typically remains silent until triggered by specific anesthetic gases or the muscle relaxant succinylcholine. You cannot "self-diagnose" this condition; it is identified through a combination of detailed family medical history, specialized genetic testing, or, in rare cases, a muscle biopsy.

What are the early signs and symptoms of Malignant hyperthermia?

Because Malignant hyperthermia is a reaction to anesthesia, it is rarely experienced in daily life. The primary clinical signs occur during or shortly after a surgical procedure involving triggering agents. These include a rapid, unexplained rise in body temperature (hyperthermia), rigid muscles (particularly in the jaw), rapid heart rate (tachycardia), and dark, tea-colored urine indicating muscle breakdown (rhabdomyolysis). It is important to remember that for the vast majority of people, Malignant hyperthermia remains completely asymptomatic until a triggering event occurs.

How can I assess my risk for Malignant hyperthermia?

The most effective way to assess your risk is to investigate your family history. Malignant hyperthermia follows an autosomal dominant inheritance pattern, meaning if a parent has the genetic mutation, there is a 50% chance of passing it to their children. You should look for patterns such as:

• Unexplained deaths during surgery among blood relatives.


• History of high fevers or muscle complications following anesthesia in family members.


• A diagnosis of related myopathies, such as Central Core Disease, which are sometimes linked to the risk of Malignant hyperthermia.

When should I talk to my doctor and what tests are available?

If you suspect a family history of Malignant hyperthermia, you should consult an anesthesiologist or a clinical geneticist before any scheduled surgery. They will conduct a thorough review of your medical records. The gold standard for diagnosis is the Caffeine-Halothane Contracture Test (CHCT), which requires a muscle biopsy. Alternatively, genetic testing for mutations in the RYR1 gene (and less commonly the CACNA1S gene) can identify the condition without a biopsy. Genetic testing is often the first step, though it cannot detect every possible mutation associated with Malignant hyperthermia.

What are the red flags requiring urgent attention?

If you have a known or suspected susceptibility to Malignant hyperthermia, any unexplained muscle rigidity or dark urine following a surgical procedure is a medical emergency. You should always carry a medical alert bracelet or ID card stating your susceptibility. If you feel your concerns are being dismissed by a medical provider, firmly request a consultation with an anesthesiologist who specializes in rare pharmacogenetic disorders or contact the Malignant Hyperthermia Association of the United States (MHAUS) for resources to share with your surgical team.

What is the difference between normal variation and symptoms?

It is common to worry about muscle aches or temperature fluctuations, but these are rarely signs of Malignant hyperthermia. Normal muscle soreness, post-surgical shivering, or common fevers are not indicative of this condition. Malignant hyperthermia is a very specific, acute, and life-threatening reaction to anesthesia, not a chronic illness that manifests through daily symptoms.

Next steps

• Gather detailed surgical and anesthesia records from your biological family members.


• Consult with a clinical geneticist to discuss whether RYR1 gene testing is appropriate for you.


• Join the DiseaseMaps.org community to connect with other patients who have navigated the challenges of living with susceptibility to Malignant hyperthermia.


• Always inform your surgeon and anesthesiologist of your family history well in advance of any operation.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• Malignant Hyperthermia Association of the United States (MHAUS) - mhaus.org


• NIH Genetic and Rare Diseases Information Center (GARD) - rarediseases.info.nih.gov


• Orphanet: Portal for rare diseases and orphan drugs - orpha.net


• Online Mendelian Inheritance in Man (OMIM) - omim.org